FOLH1 and prostate cancer: Notably, transfer of either retargeted or parental NK-92 cells did not significantly impact on the progression of PSMA-negative PC3 tumors (Figure 5A, right panel), thus reinforcing the concept that the effects observed against antigen-expressing prostate cancer were strictly CAR-dependent.